WO2001082894A3 - Directly compressed solid dosage particles - Google Patents

Directly compressed solid dosage particles Download PDF

Info

Publication number
WO2001082894A3
WO2001082894A3 PCT/US2001/012400 US0112400W WO0182894A3 WO 2001082894 A3 WO2001082894 A3 WO 2001082894A3 US 0112400 W US0112400 W US 0112400W WO 0182894 A3 WO0182894 A3 WO 0182894A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid dosage
directly compressed
compressed solid
copolymer
active ingredient
Prior art date
Application number
PCT/US2001/012400
Other languages
French (fr)
Other versions
WO2001082894A2 (en
Inventor
William R Wilber
Jian-Hwa Guo
Edward S Greenberg
Original Assignee
Noveon Ip Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noveon Ip Holdings Corp filed Critical Noveon Ip Holdings Corp
Priority to IL15246101A priority Critical patent/IL152461A0/en
Priority to EP01925043A priority patent/EP1276466B1/en
Priority to AT01925043T priority patent/ATE255886T1/en
Priority to BR0110287-7A priority patent/BR0110287A/en
Priority to MXPA02010437A priority patent/MXPA02010437A/en
Priority to CA002407140A priority patent/CA2407140A1/en
Priority to JP2001579769A priority patent/JP2003531848A/en
Priority to DE60101468T priority patent/DE60101468T2/en
Publication of WO2001082894A2 publication Critical patent/WO2001082894A2/en
Publication of WO2001082894A3 publication Critical patent/WO2001082894A3/en
Priority to IL152461A priority patent/IL152461A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

Solid dosage articles such as pharmaceutical tablets for the controlled release of a desired compound such as an active ingredient are directly compressed from a flowable, compressible mixture of the active ingredient, a slightly cross-linked rheology modifying polymer or copolymer, and one or more excipients. The rheology modifying polymer or copolymer is a granulated powder of suitable particle size and is generally made from one or more unsaturated (di)carboxylic acids, half ester thereof, and other optional monomers.
PCT/US2001/012400 2000-04-27 2001-04-17 Directly compressed solid dosage particles WO2001082894A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL15246101A IL152461A0 (en) 2000-04-27 2001-04-17 Directly compressed solid dosage articles
EP01925043A EP1276466B1 (en) 2000-04-27 2001-04-17 Directly compressed solid dosage particles
AT01925043T ATE255886T1 (en) 2000-04-27 2001-04-17 DIRECT COMPRESSED PARTICLES FOR SOLID DOSAGE FORMS
BR0110287-7A BR0110287A (en) 2000-04-27 2001-04-17 Solid release and controlled release articles, process for direct compression of solid dosage articles, directly compressible mixing, and process for forming the same
MXPA02010437A MXPA02010437A (en) 2000-04-27 2001-04-17 Directly compressed solid dosage particles.
CA002407140A CA2407140A1 (en) 2000-04-27 2001-04-17 Directly compressed solid dosage particles
JP2001579769A JP2003531848A (en) 2000-04-27 2001-04-17 Direct compression solid dosage product
DE60101468T DE60101468T2 (en) 2000-04-27 2001-04-17 DIRECTLY COMPRESSED PARTICLES FOR FIXED PHARMACEUTICAL FORMS
IL152461A IL152461A (en) 2000-04-27 2002-10-24 Directly compressed solid dosage articles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/559,687 2000-04-27
US09/559,687 US6623756B1 (en) 2000-04-27 2000-04-27 Directly compressed solid dosage articles

Publications (2)

Publication Number Publication Date
WO2001082894A2 WO2001082894A2 (en) 2001-11-08
WO2001082894A3 true WO2001082894A3 (en) 2002-02-21

Family

ID=24234605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012400 WO2001082894A2 (en) 2000-04-27 2001-04-17 Directly compressed solid dosage particles

Country Status (13)

Country Link
US (1) US6623756B1 (en)
EP (1) EP1276466B1 (en)
JP (1) JP2003531848A (en)
CN (1) CN1195498C (en)
AT (1) ATE255886T1 (en)
BR (1) BR0110287A (en)
CA (1) CA2407140A1 (en)
DE (1) DE60101468T2 (en)
ES (1) ES2211796T3 (en)
IL (2) IL152461A0 (en)
MX (1) MXPA02010437A (en)
WO (1) WO2001082894A2 (en)
ZA (1) ZA200208571B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
US20030012820A1 (en) * 2001-06-12 2003-01-16 Upadhyay Ajay Hasmukhlal Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
US6705028B2 (en) * 2001-09-12 2004-03-16 Honda Giken Kogyo Kabushiki Kaisha Self-propelled snowplow vehicle
US20040185016A1 (en) * 2002-07-30 2004-09-23 Popp Karl F Compositions for treatment of hyperpigmentation and methods for making and using such compositions
US20040219210A1 (en) * 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
FI20080353A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with extra high drug content
FI20080346A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for making a tablet containing additives
FI20080355A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for making tablets containing metformin
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
CN101467988B (en) * 2007-12-27 2014-07-09 北京德众万全医药科技有限公司 Medicament composition containing paracetamol and pseudoephedrine hydrochloride and preparation method thereof
US20110284573A1 (en) * 2008-12-17 2011-11-24 Allan Dagsland Method of providing a target dose, powder provider device and its use
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
AR079528A1 (en) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc 5,5-FUSIONED ARYLENE OR HETEROARYLENE INHIBITORS OF HEPATITIS C VIRUS
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
WO2012030913A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611792B1 (en) 2010-09-01 2017-02-01 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
JP2014503597A (en) 2011-01-31 2014-02-13 セルジーン コーポレイション Pharmaceutical composition of cytidine analogue and method of use thereof
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CA2943231C (en) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
HUE049801T2 (en) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopyrazole kinase inhibitors
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
JP2022520011A (en) 2019-01-24 2022-03-28 ノヴォ ノルディスク アー／エス Dry granulation method using roller compactor and roller compactor
WO2021043971A1 (en) 2019-09-06 2021-03-11 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3915921A (en) * 1974-07-02 1975-10-28 Goodrich Co B F Unsaturated carboxylic acid-long chain alkyl ester copolymers and tri-polymers water thickening agents and emulsifiers
US4267103A (en) * 1978-12-07 1981-05-12 The B. F. Goodrich Company Solvent polymerization of carboxyl containing monomers
DE3888520T2 (en) * 1988-03-30 1994-07-21 Japan Synthetic Rubber Co Ltd Highly crosslinked polymer particles and process for making the same.
ATE209228T1 (en) 1992-05-09 2001-12-15 Surfachem Group Ltd CONVERSION OF POWDERED POLYMERS
US5288814A (en) * 1992-08-26 1994-02-22 The B. F. Goodrich Company Easy to disperse polycarboxylic acid thickeners
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ÇELEBI N ET AL: "DEVELOPMENT AND EVALUATION OF A BUCCOADHESIVE PROPANOLOL TABLET FORMULATION", PHARMAZIE, VEB VERLAG VOLK UND GESUNDHEIT. BERLIN, DD, vol. 50, no. 7, 1 July 1995 (1995-07-01), pages 470 - 472, XP000511715, ISSN: 0031-7144 *
HANCOCK BC; CARLSON GT: "The powder flow and compact mechanical properties of two recntly developed matrix-forming polymers", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 53, no. 9, - 2001, pages 1193 - 1199, XP001030894 *
HUANG L.L; SCHWARZ JB: "Studies on drug release from a carbomer tablet matrix", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 21, - 1995, pages 1487 - 1501, XP001030981 *
KIBBE A.H: "Handbook of pharmaceutical excipients, 3rd edition", APHA, WASHINGTON, XP002181573 *
MESHALI M.M ET AL.: "Preparation and evaluation of theophylline sustained-release tablets", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 22, 1996, pages 373 - 376, XP001030992 *
OFOELULE S.I; CHUKWU A: "Use of acryli", BOLLETINO CHIMICO FARMACEUTICO, vol. 138, no. 10, 1999, pages 526 - 530, XP001030890 *

Also Published As

Publication number Publication date
DE60101468T2 (en) 2004-10-28
ATE255886T1 (en) 2003-12-15
IL152461A (en) 2007-08-19
ZA200208571B (en) 2003-08-19
IL152461A0 (en) 2003-05-29
CN1426297A (en) 2003-06-25
CN1195498C (en) 2005-04-06
WO2001082894A2 (en) 2001-11-08
EP1276466A2 (en) 2003-01-22
BR0110287A (en) 2003-02-18
CA2407140A1 (en) 2001-11-08
ES2211796T3 (en) 2004-07-16
JP2003531848A (en) 2003-10-28
US6623756B1 (en) 2003-09-23
EP1276466B1 (en) 2003-12-10
DE60101468D1 (en) 2004-01-22
MXPA02010437A (en) 2003-04-25

Similar Documents

Publication Publication Date Title
WO2001082894A3 (en) Directly compressed solid dosage particles
EP2258345A3 (en) Solid pharmaceutical dosage form comprising an HIV protease inhibitor solid dispersion
EP0381219B1 (en) Modified release gemfibrozil composition
AU767671B2 (en) Directly compressible, ultra fine acetaminophen compositions and process for producing same
CA2217462A1 (en) Controlled release biodegradable micro- and nanospheres containing cyclosporin
CA2198630A1 (en) Acetaminophen sustained-release formulation
CA2152795A1 (en) Readily available konjac glucomannan sustained release excipient
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
CA2385890A1 (en) Controlled release compositions comprising nimesulide
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2002089773A3 (en) Pharmaceutical compositions comprising cyclosporin
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
BG102228A (en) Medicamentous form with controlled release of slightly soluble medicamentous substances
EP2277510A3 (en) Controlled release preparation
CA2231195A1 (en) Sustained release matrix for high-dose insoluble drugs
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
WO2005011570A3 (en) Calcium carbonate granulation
AU5002499A (en) Controlled release polyacrylic acid granules and a process for preparing the same
CA2445519A1 (en) Method for manufacturing a low dose pharmaceutical composition
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
WO2005123045A3 (en) Controlled release matrix pharmaceutical dosage formulation
PT1195160E (en) Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
GEP20033078B (en) Controlled-Release Compositions of Betahistine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BR CA CN HU IL JP MX ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): BR CA CN HU IL JP MX ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001925043

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 579769

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2002/08571

Country of ref document: ZA

Ref document number: PA/a/2002/010437

Country of ref document: MX

Ref document number: 200208571

Country of ref document: ZA

Ref document number: 2407140

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 152461

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 018086330

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001925043

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001925043

Country of ref document: EP